Skip to main content
BioMarin shares plans for hemophilia A gene therapy candidate valrox
8/5/2019

After its announcement of a modest increase in second quarter revenues, BioMarin outlined plans for its hemophilia A gene therapy candidate valrox, or valoctocogene roxaparvovec, including the submission of marketing applications in the US and Europe.

Full Story: